What is Ionis Pharmaceuticals's bepirovirsen — revenue?

Ionis Pharmaceuticals (IONS) reported bepirovirsen — revenue of $15M in Q1 2023.

What does bepirovirsen — revenue mean?

The total revenue generated from the Bepirovirsen drug program through commercial or partnership agreements.

How do you interpret bepirovirsen — revenue?

An increase indicates successful clinical progression, milestone achievement, or growing market demand for the Bepirovirsen therapy. A decrease may signal delays in clinical development, regulatory hurdles, or lower-than-expected commercial uptake.

How does bepirovirsen — revenue compare across companies?

Comparable to product-specific revenue or licensing milestone income reported by other biotechnology firms focused on rare disease or specialty pharmaceutical pipelines.

Ionis Pharmaceuticals IONS Bepirovirsen — Revenue

Discontinued — last reported Q1 '23

Other product segments

Research And Development Revenue

$138.28M+149%

Collaborative Agreement Revenue

$120.66M+168%

Commercial

$107.81M+41.5%

Royalty

$58.32M-9.1%

Spinraza Royalties

$43.71M-9.0%

Tryngolza

$27.1M+331%

Wainua Joint Development Revenue

$17.62M+69.2%

Wainus Royalties

$10.71M+14.3%

Other Commercial

$6.53M+14.3%

Other Royalties

$3.9M-42.5%

Similar metrics at other companies

BBIOLicense And Services Revenue — Revenue

$37.44M+1,627%

BBIONet Product Revenue — Revenue

$71.5M—

BIIBZINBRYTA — Revenue

$0—

BIIBBiosimilars — Total Revenue

$182.2M+0.8%

BBIORoyalty Revenue — Revenue

$1.62M—

BBIOLicense Revenue — Revenue

$75M—

Other financials

Income statement

See full

Revenue$246.1M+87.0%

Gross profit$243.1M+86.8%

Operating income-$117.4M+20.0%

Net income-$92.5M+37.0%

EPS (diluted)-$0.56+39.8%

Balance sheet

See full

Cash & equivalents$173.4M-34.4%

Total debt$691.7M+334%

Total equity$491.4M+3.3%

Total assets$3.4B+22.6%

Cash flow

See full

Operating cash flow-$792.8M-426%

CapEx$21.8M+73.0%

Free cash flow-$814.6M-399%

Valuation

See full

Market cap$12.25B+159%

Enterprise value$12.77B+175%

P/S11.6×+5.0×

Profitability

See full

Gross margin98.4%-0.2pp

Operating margin-33.3%-11.0pp

Net margin-30.9%-10.5pp

FCF margin-77.4%+35.3pp

Returns & leverage

See full

Return on equity-67.6%-20.3pp

Debt / equity1.4×+1.1×

Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Ionis Pharmaceuticals’s 10-Q, filed November 2, 2023, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's bepirovirsen — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ionis Pharmaceuticals's bepirovirsen — revenue?: Ionis Pharmaceuticals (IONS) reported bepirovirsen — revenue of $15M in Q1 2023.
What does bepirovirsen — revenue mean?: The total revenue generated from the Bepirovirsen drug program through commercial or partnership agreements.
How do you interpret bepirovirsen — revenue?: An increase indicates successful clinical progression, milestone achievement, or growing market demand for the Bepirovirsen therapy. A decrease may signal delays in clinical development, regulatory hurdles, or lower-than-expected commercial uptake.
How does bepirovirsen — revenue compare across companies?: Comparable to product-specific revenue or licensing milestone income reported by other biotechnology firms focused on rare disease or specialty pharmaceutical pipelines.